0.13
-0.004(-3.08%)
Currency In USD
Address
50 Hampshire Street
Cambridge, MA 02139
United States of America
Phone
857 320 6400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
October 02, 2020
| Name | Title | Pay | Year Born |
| Mr. Brian J. Shea | Pres, Interim Chief Executive Officer, Gen. Counsel & Corporation Sec. | 0 | N/A |
| Mr. Craig R. Jalbert CIRA | Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary & Director | 0 | 1962 |
| Dr. Mitchell H. Finer Ph.D. | Non-Executive Director | 60,548 | 1959 |
| Dr. John Mayer Goldberg M.D. | Chief Medical Officer | 552,030 | 1974 |
| Mr. Stephen W. Harbin | Chief Operating Officer & Chief of Staff | 786,150 | 1959 |
| Brian J. Shea | Director of Legal Counsel & Corporation Sec. | 0 | N/A |
| Mr. Richard J. Wanstall M.B.A. | Chief Financial Officer, Chief Accounting Officer & Treasurer | 0 | 1969 |
| Mr. Alexander Nolte | Interim Chief Financial Officer, Principal Accounting Officer & Treasurer | 0 | 1973 |
| Chris German | Controller | 0 | N/A |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.